Zacks Research Has Optimistic Outlook of TEVA Q2 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Equities research analysts at Zacks Research upped their Q2 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a report released on Thursday, April 3rd. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.61 per share for the quarter, up from their prior forecast of $0.60. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.71 EPS, Q3 2025 earnings at $0.71 EPS, Q1 2027 earnings at $0.62 EPS and Q1 2027 earnings at $0.62 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%.

TEVA has been the topic of several other research reports. Bank of America cut their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Finally, Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $13.83 on Friday. The company has a market cap of $15.68 billion, a price-to-earnings ratio of -9.54, a PEG ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80. The stock has a fifty day moving average price of $16.52 and a 200-day moving average price of $18.01.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in the company. FMR LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd increased its stake in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after purchasing an additional 4,418,961 shares during the period. Ion Asset Management Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 1.1% during the fourth quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock worth $807,766,000 after purchasing an additional 409,778 shares during the last quarter. Lingotto Investment Management LLP boosted its stake in shares of Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after purchasing an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after purchasing an additional 569,412 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.